| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Leukemia, Lymphoid | |||||
| Lymphoma, Non-Hodgkin | |||||
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| BL22 immunotoxin | |||||
| antibody-drug conjugate therapy | |||||
| immunotoxin therapy | |||||
| monoclonal antibody therapy | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Antibodies | |||||
| Antibodies, Monoclonal | |||||
| Immunotoxins | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| MedImmune LLC | |||||
| Cambridge Antibody Technology | |||||
|
